rethinkTHC Search
Menu
Study breakdown

Medical Cannabis for Children: Limited Evidence Supports Only Specific Cases Under Close Supervision

ReviewModerate evidence
The takeaway

A clinical review found insufficient evidence for medical cannabis efficacy or safety in children for any condition, with growing data suggesting possible harm, though specific cases like refractory epilepsy may warrant carefully monitored use.

Read this if you are a parent considering medical cannabis for a child or a clinician advising families about pediatric cannabis use.

Insufficient data to support cannabis efficacy or safety for any pediatric indication as of 2016.

What the researchers found

This clinical review examined the evidence for medical cannabis use in children, prompted by case reports of children with refractory epilepsy responding to cannabis-based treatments. The author concluded that overall evidence is insufficient to support either the efficacy or safety of cannabis use for any indication in children.

The review emphasized several concerns: an increasing body of data suggests possible harm, particularly in conditions where the developing brain may be vulnerable. Smoking is explicitly rejected as an acceptable delivery method for children. The review also cautioned that therapeutic use in specific medical cases should not be used to justify recreational cannabis use by adolescents.

Despite these concerns, the author acknowledged that exceptional cases exist where standard treatments have failed, and offered recommendations for therapeutic use in these circumstances: always under careful individual evaluation, within well-designed research studies, and with ongoing monitoring for both safety and efficacy.

Why it matters

Medical cannabis for children is among the most contentious topics in pediatric medicine. This review from a mainstream pediatric journal represents the medical establishment's cautious position: acknowledge that some children may benefit, particularly those with refractory epilepsy, but insist on rigorous evaluation and monitoring rather than broad access.

The numbers in context

No specific numerical data were presented; the review synthesized existing evidence and provided clinical recommendations.

How the study worked

This was a narrative clinical review published in Paediatrics & Child Health (a journal of the Canadian Paediatric Society), summarizing available evidence on cannabis use in pediatric populations and providing clinical recommendations.

What this study cannot tell us

This is a narrative review reflecting one author's interpretation of available evidence, published before many subsequent clinical trials of pharmaceutical-grade CBD products in pediatric epilepsy. The review predates the FDA approval of Epidiolex (cannabidiol) for pediatric seizure disorders.

How to read the evidence

Moderate evidence from a narrative clinical review in a reputable pediatric journal, synthesizing available data and providing consensus-oriented recommendations.

When this study was published

Published in 2016, before the FDA approved Epidiolex (CBD) for pediatric epilepsy in 2018. The evidence landscape for pediatric cannabis use has changed significantly.

The bigger picture

The tension between anecdotal reports of children with severe epilepsy responding dramatically to cannabis-based treatments and the lack of rigorous safety and efficacy data exemplifies the broader challenge of cannabis medicine. The stakes are especially high in children because of the developing brain's sensitivity to cannabinoids.

Questions still open

  • Have subsequent clinical trials of pharmaceutical CBD products changed the risk-benefit calculus for children with epilepsy? Should cannabis-based treatments for children be limited to pharmaceutical-grade products with standardized dosing? How do we balance parental autonomy with medical caution when standard treatments fail?

Common questions

Is medical cannabis safe for children?
As of this 2016 review, there was insufficient evidence to establish safety for any pediatric use. The review noted growing data suggesting possible harm to the developing brain. Since then, pharmaceutical CBD (Epidiolex) has been approved for specific seizure disorders with established dosing and monitoring protocols.
Can cannabis treat childhood epilepsy?
Case reports existed at the time of this review showing benefit for refractory epilepsy. The author recommended use only in exceptional cases with careful monitoring. Since 2018, pharmaceutical CBD has received FDA approval for specific pediatric seizure disorders based on clinical trial evidence.

Read the original research

Is the medical use of cannabis a therapeutic option for children?

Paediatrics & child health, 21(1), 31-4

Citation

Rieder, Michael J. (2016). Is the medical use of cannabis a therapeutic option for children?. Paediatrics & child health, 21(1), 31-4.

Explore the wider topic